This is consistent with an analysis of FSHD muscle biopsies, where DUX4 protein could be found in some samples, but was never detected in those of severely affected patients [51], emphasizing the impact of long-term vivoPMO-PACS4 treatment in a model that more closely represents the human condition. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.